';
Featured
Featured posts

This fall, the National Alliance for Direct Support Professionals announced that it would be conducting a comprehensive campaign across the country to address COVID-19 vaccine hesitancy among direct support professionals. This initiative is part of a cooperative agreement with the Association of University Centers on Disabilities (AUCD), funded by the Centers for Disease Control and Prevention (CDC).
During this year-long campaign, NADSP is launching a variety of outreach activities including fact sheets, blogs, podcasts, and the production of public service announcements (PSAs).

In November, NADSP’s Director of Educational Services, John Raffaele, worked with filmmaker Jerry Smith and producer Pete McCauley of the Institute on Community Integration at the University of Minnesota to capture some important and thought-provoking conversations.

This video is the first of many PSAs featuring DSPs, family members, and people receiving supports who shared varying perspectives on COVID-19 vaccination. Uwvie Obodo, a direct support professional at the Center for Family Support  in New York City, shares his experience below.

To learn more about John’s experiences during the first phase of filming, and the new insight he gained into why 26% of DSPs remain unvaccinated, visit the “Read More” section.


COVID-19 Webinars

Since the onset of COVID-19, NADSP has hosted a number of webinars about the pandemic — specifically covering its relationship to the role and responsibilities of direct support professionals.

The Office of Developmental Programs (ODP) is sharing information from the Centers for Disease Control and Prevention (CDC) on safe ways to celebrate the holidays. Currently across the United States, an increase in COVID-19 infections is being reported. Omicron, the latest COVID-19 variant of concern, is highly contagious, was first detected last month, and has now been reported in 89 countries. As of December 20, 2021, Omicron has been detected in most states and territories and is rapidly increasing the proportion of COVID-19 cases it is causing.

Current vaccines are expected to protect against severe illness, hospitalizations, and deaths due to infection with the Omicron variant. However, breakthrough infections in people who are fully vaccinated are likely to occur. With other variants, like Delta, vaccines have remained effective at preventing severe illness, hospitalizations, and death. The recent emergence of Omicron further emphasizes the importance of vaccination and boosters.

The CDC reminds us of the tools to fight Omicron:

Vaccines

  • Vaccines remain the best public health measure to protect people from COVID-19, slow transmission, and reduce the likelihood of new variants emerging.
  • COVID-19 vaccines are highly effective at preventing severe illness, hospitalizations, and death.
  • Scientists are currently investigating Omicron, including how protected fully vaccinated people will be against infection, hospitalization, and death.
  • CDC recommends that everyone 5 years and older protect themselves from COVID-19 by getting fully vaccinated.
  • CDC recommends that everyone ages 18 years and older should get a booster shot at least two months after their initial J&J/Janssen vaccine or six months after completing their primary COVID-19 vaccination series of Pfizer-BioNTech or Moderna.

Masks

  • Masks offer protection against all variants.
  • CDC continues to recommend wearing a mask in public indoor settings in areas of substantial or high community transmission, regardless of vaccination status.
  • CDC provides advice about masks for people who want to learn more about what type of mask is right for them depending on their circumstances.

Testing

  • Tests can tell you if you are currently infected with COVID-19.
  • Two types of tests are used to test for current infection: nucleic acid amplification tests (NAATs) and antigen tests. NAAT and antigen tests can only tell you if you have a current infection.
  • Additional tests would be needed to determine if your infection was caused by Omicron.
  • Self Testing for Individuals Living in a Private Home:
    • Self-tests can be used at home or anywhere, are easy to use, and produce rapid results.
    • If the self-test has a positive result, stay home or isolate for 10 days, wear a mask if you have contact with others, and call your healthcare provider.
    • If you have any questions about your self-test result, call your healthcare provider or public health department.

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) recently updated its Department Funding web page to include documents outlining how the department is spending its funding by source, including:

  • Supplemental Funding;
  • Substance Abuse Prevention & Treatment Block Grant Supplemental Funding;
  • American Rescue Plan;
  • State Opioid Response II;
  • McKinsey Settlement; and
  • Medical Marijuana Revenue.

DDAP will update this page as new funding sources are announced.

Photo by Markus Winkler on Unsplash

Following the Commonwealth Court’s decision to deny the Drug and Alcohol Service Providers Organization of Pennsylvania’s (DASPOP) request for a preliminary injunction against key pieces of the ASAM transition, the Department of Drug and Alcohol Programs (DDAP) participated in RCPA’s Drug and Alcohol Committee meeting on Tuesday, Dec. 14. You can read the court’s opinion here.

Despite establishing a deadline by which providers must align with the ASAM Criteria, including the “PA-Specific Alignment Requirements,” and in particular referencing the changes in IOP ratio, daily therapeutic hours, and credentialing as “PA-Specific Alignment Requirements” of the ASAM transition on its website, DDAP argued in court that these are “guidelines,” not requirements. The challenge for providers, however, is that the single county authorities (SCAs) and behavioral health managed care organizations (BHMCOs) have signaled all along that they will require providers to comply with these pieces of the ASAM transition through contracts. Now, DDAP’s pivot to calling them “guidelines” has created confusion among providers and payers. RCPA has contacted each of the five BHMCOs and the Pennsylvania Association of County Drug and Alcohol Administrators (PACDAA) to ask whether DDAP’s testimony and the court’s decision will change their approach to enforcing the guidelines/mandates in question through their contracts. We will pass along any relevant information we may receive. In addition, DDAP told us it will be issuing guidance and clarification on these guidelines right before or after the new year.

At RCPA’s D&A Committee meeting last week, DDAP Deputy Secretary Ellen DiDomenico explained how ASAM explicitly defines its criteria versus DDAP’s interpretation of that criteria and what it is now calling recommended guidelines. For example, while the ASAM Criteria explicitly calls for daily clinical hours, DDAP has established six to eight daily therapeutic hours as the application of ASAM’s criteria in Pennsylvania. As DDAP has communicated all along, Deputy Secretary DiDomenico explained that if providers can demonstrate the ability to provide individualized care in ways other than what DDAP “recommends,” it will consider those.

DDAP also said at the meeting that nothing has changed with the court’s decision, which we would interpret to mean that unless a provider has been approved to provide care in a way other than what DDAP recommends, providers must be aligned with their guidelines by Jan. 1, 2022. For example, unless a provider has been approved to provide intensive outpatient services at a ratio other than 1:15, that provider must meet the 1:15 guideline. DDAP also said at the meeting that it is working with the MCOs and SCAs to develop a monitoring tool with the goal being development of a collaborative monitoring process so that providers will not need to be monitored for ASAM alignment by multiple payers. Deputy Secretary DiDomenico also said that monitoring of ASAM compliance would focus on ASAM Criteria as explicitly written in the ASAM Criteria 3rd Edition.

Lastly, House Bill 1995, which would have forced DDAP to go through the regulatory review process any time it made changes that affect licensed addiction treatment providers, has stalled in the Senate. After sailing out of the House of Representatives on a timeline that would have enabled it to pass the Senate and land on the governor’s desk before Jan. 1, the Senate Health and Human Services Committee did not take up the bill for vote. With the General Assembly recessed through the end of the year, there is no possibility of HB 1995 providing relief to providers on the confusion around these ASAM guidelines before Jan. 1.

Given the contradictions and confusion, we will share any guidance we get from DDAP as soon as we get it. Please contact RCPA Drug and Alcohol Division Director Jason Snyder with any questions.